share_log

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Pfizer Inc. (“Pfizer”)(0.0%)

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Pfizer Inc. (“Pfizer”)(0.0%)

辉瑞 | SC 13D/A：超过5%持股股东披露文件(修正)-Pfizer Inc. (“Pfizer”)(0.0%)
美股SEC公告 ·  08/05 18:12

Moomoo AI 已提取核心信息

On August 1, 2024, Pfizer Inc. reported the completion of a merger between Cerevel Therapeutics Holdings, Inc. and Symphony Harlan Merger Sub Inc., a subsidiary of AbbVie Inc. The merger resulted in Cerevel becoming a wholly owned subsidiary of AbbVie. At the effective time of the merger, each share of Cerevel's common stock was converted into the right to receive $45.00 per share in cash, excluding certain specified shares. This transaction was finalized as disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Following the merger, Cerevel's common stock ceased trading on The Nasdaq Capital Market and was delisted. Pfizer, which had beneficially owned shares in Cerevel, reported owning 0 shares post-merger, marking this filing as an 'exit filing' for the company.
On August 1, 2024, Pfizer Inc. reported the completion of a merger between Cerevel Therapeutics Holdings, Inc. and Symphony Harlan Merger Sub Inc., a subsidiary of AbbVie Inc. The merger resulted in Cerevel becoming a wholly owned subsidiary of AbbVie. At the effective time of the merger, each share of Cerevel's common stock was converted into the right to receive $45.00 per share in cash, excluding certain specified shares. This transaction was finalized as disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Following the merger, Cerevel's common stock ceased trading on The Nasdaq Capital Market and was delisted. Pfizer, which had beneficially owned shares in Cerevel, reported owning 0 shares post-merger, marking this filing as an 'exit filing' for the company.
2024年8月1日，辉瑞公司报告称，Cerevel Therapeutics Holdings与Symphony Harlan Merger Sub Inc. ，AbbVie的子公司完成了一次合并。此次合并导致Cerevel成为AbbVie的全资子公司。在合并生效时，Cerevel每股普通股转换为每股45.00美元的现金权利，不包括特定指定股份。此交易已在提交给美国证券交易委员会的8-K表格中公开披露。合并完成后，Cerevel的普通股于纳斯达克资本市场停止交易并下线。辉瑞公司曾持有Cerevel的部分股份，合并后报告不再持有任何股份，并标记此次申报为公司的“退出申报”。
2024年8月1日，辉瑞公司报告称，Cerevel Therapeutics Holdings与Symphony Harlan Merger Sub Inc. ，AbbVie的子公司完成了一次合并。此次合并导致Cerevel成为AbbVie的全资子公司。在合并生效时，Cerevel每股普通股转换为每股45.00美元的现金权利，不包括特定指定股份。此交易已在提交给美国证券交易委员会的8-K表格中公开披露。合并完成后，Cerevel的普通股于纳斯达克资本市场停止交易并下线。辉瑞公司曾持有Cerevel的部分股份，合并后报告不再持有任何股份，并标记此次申报为公司的“退出申报”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间